Fundz

Zymeworks to acquire Theravance Biopharma for $17/share

PUBLIC · ZYMEJun 29, 2026

Acquiring Company

ZYMEWORKS

Acquired Company

Theravance Biopharma

DublinBiotechnologyBiotechnologyHealth Care

Description

Zymeworks Inc. has entered into a definitive agreement to acquire Theravance Biopharma for $17.00 per share in cash, totaling approximately $929 million. In addition to the cash, Theravance shareholders will receive a contingent value right based on future monetization of ampreloxetine. The transaction aims to maximize shareholder value and follows a comprehensive strategic review process.

Who to call at ZYMEWORKS, and when

When ZYMEWORKS changes hands, the new owners review vendors, systems and leadership. That is when the door opens.

  • An alert the day ZYMEWORKS raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at ZYMEWORKS, from your own LinkedIn network
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

ZYMEWORKS

Location

114 E 4th Avenue, Suite 800

About

Zymeworks Inc. (Nasdaq: ZYME) is a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks' mission is to make a meaningful difference for people impacted by difficult-to-treat cancers and other serious diseases. Zymeworks' complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using Zymeworks' proprietary AzymetricTM technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each of BeiGene and Jazz with exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in global Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials as a treatment for patients with HER2-expressing cancers. Zymeworks' next clinical candidate, zanidatamab zovodotin (ZW49), is a HER2-targeted bispecific antibody-drug conjugate (ADC) developed using Zymeworks' proprietary AzymetricTM and ZymeLinkTM Auristatin technologies. Zanidatamab zovodotin is being evaluated in a Phase 2 clinical trial for patients with HER2-expressing non-small cell lung cancer. Zymeworks is also advancing a deep pipeline of product candidates based on its experience and capabilities in both ADC and multispecific antibodies (MSAT), including planned IND filings for ZW171 and ZW191 in 2024. In addition to Zymeworks' wholly owned pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment ZYMEWORKS makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Paul
Likely contact at this company
••••••••@••••••••

See Paul's verified email →

Suzanne
Likely contact at this company
••••••••@••••••••

See Suzanne's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for ZYMEWORKS's next move

Learn about Strategic plan

Frequently asked

Who acquired Theravance Biopharma?

Theravance Biopharma was acquired by ZYMEWORKS. The deal was reported on June 29, 2026. Zymeworks Inc. (Nasdaq: ZYME) is a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. ZYMEWORKS is publicly traded (ZYME) and operates in Biotechnology.

When did ZYMEWORKS acquire Theravance Biopharma?

ZYMEWORKS's acquisition of Theravance Biopharma was reported on June 29, 2026. Zymeworks Inc. has entered into a definitive agreement to acquire Theravance Biopharma for $17.00 per share in cash, totaling approximately $929 million. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Theravance Biopharma do?

Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference® in people's lives. It is privately held, operating in Biotechnology, and is based in Dublin.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.